High phosphorous intake associated with increased risk of lethal prostate cancer
the ONA take:
According to a new study published in the American Journal of Clinical Nutrition, phosphorous is independently associated with the risk of developing lethal and high-grade prostate cancer.
Researchers identified nearly 48,000 men who reported their diet in 1986 and every 4 years thereafter. During the 24-year follow-up, 5,861 participants developed prostate cancer, 789 of which were lethal cancers. Results showed phosphorous intake was linked with a greater risk for developing prostate cancer, including lethal and high-grade disease.
This association was independent of calcium and dairy, fish, red meat, and white meat intake. In addition, high calcium intake was associated with an elevated risk for developing advanced-stage and high-grade disease 12 to 16 years after exposure.
High phosphorous intake was linked with an increased risk for developing advanced-stage and high-grade prostate cancer 0 to 8 years after exposure. Foods high in phosphorous include: seeds, lentils, cheese, colas, shellfish, and yogurt.
Phosphorous is independently associated with the risk of developing lethal and high-grade prostate cancer.
- Neurotoxicity After CAR T-cell Therapy May Be Associated With Endothelial Activation
- Navigation Programs Most Effective in Increasing Follow-up Colonoscopy
- New Class of Clinical Trial Enhances Research on Cancer Care Delivery
- Specialized Interventions Reduce Aberrant Opioid Behaviors in Cancer Patients
- Nivolumab Provides Better Long-Term Efficacy Compared With Docetaxel in NSCLC
- Anticancer Properties of The Probiotic Kefir: A Review
- Navigating the Transition From Treatment to Breast Cancer Survivor
- Combining Radiation, Immunotherapy: An Emerging Challenge for Oncology Nursing
- Naldemedine Effective for Opioid-Induced Constipation in Cancer Pain
- Disruptions to Circadian Rhythm Linked to Prostate Cancer Surgery Regret
- Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy
- Novel Predictive Model More Effectively Identifies Risk for Lung Cancer
- Long-Term Eltrombopag Increases Platelet Counts, Decreases Bleeding in ITP
- Overall Survival Increase for Melanoma Brain Metastases
- Prophylactic Prochloperazine Ineffective for Opioid-induced Nausea/Vomiting in Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|